Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02933034 · ClinicalTrials.gov registry record · Phase 1
Clinical Trial of Manganese-Enhanced MRI (MEMRI) to Assess Peri-Infarct Injury
A Phase 1 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT02933034: Completed Phase 1 study, sponsored by Stanford University.
NCT02933034 is a Phase 1 study that has completed, run by Stanford University. The registered enrollment target is 33 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02933034, a Phase 1 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerance of a new intravenous diagnostic agent, SeeMore or EVP 1001-1, in patients with Cardiovascular Disease (MEMRI scan). The initial phase of this study, NCT01989195 enrolling a total of 6 patients, has been closed. This second phase adds 10 patients in a safety cohort and 60 additional patients for a total of 70 patients.
Interventions
- DRUG Manganese-enhanced MRI contrast reagent
- DRUG Gadolinium-enhanced MRI contrast reagent
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2015-04 |
| Est. Completion | 2019-02-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02933034
The ClinicalTrials.gov registry entry for NCT02933034 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Manganese-enhanced MRI contrast reagent is the first listed.
NCT02933034 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02933034 about?
NCT02933034 is a clinical study titled "Clinical Trial of Manganese-Enhanced MRI (MEMRI) to Assess Peri-Infarct Injury". The purpose of this study is to evaluate the safety and tolerance of a new intravenous diagnostic agent, SeeMore or EVP 1001-1, in patients with Cardiovascular Disease (MEMRI scan). The initial phase of this study, NCT01989195 enrolling a total of 6 patients, has been closed. This second phase adds ...
What is the current status of trial NCT02933034?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2015-04. Estimated completion is 2019-02-03.
What interventions are being tested in trial NCT02933034?
The interventions under investigation include: Manganese-enhanced MRI contrast reagent (DRUG), Gadolinium-enhanced MRI contrast reagent (DRUG).
Who is sponsoring clinical trial NCT02933034?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.